MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Annual Congress.
2 months ago